肿瘤治疗电场(TTFields)治疗高级别胶质瘤的全球上市后安全性监测
该研究回顾性分析2011年10月至2019年2月全球11,029例接受TTFields治疗的患者上市后监测数据,按地区、诊断和年龄分层。最常见不良事件为阵列相关皮肤反应(新诊断胶质母细胞瘤38%、复发胶质母细胞瘤29%),多为轻中度且可控,未发现新的安全性问题,安全性与既往试验一致。
要点
- TTFields相关不良事件以阵列皮肤反应最常见,新诊断胶质母细胞瘤38%、复发29%。
- 皮肤反应多为轻中度且可控,其他事件包括热感、电刺激感和头痛。
- 各亚组安全性一致,包括老年和儿童患者,未发现新安全性问题。
核心结论
- 对超过11,000例患者的TTFields安全性监测未发现新的安全性问题,安全性与已发表的TTFields/胶质母细胞瘤试验相当。
研究设计与样本
- 回顾性分析2011年10月至2019年2月全球接受TTFields治疗的11,029例患者的非 solicited 上市后监测数据,按地区、诊断和年龄分层。
主要发现
- 新诊断胶质母细胞瘤患者阵列相关皮肤反应发生率为38%,复发胶质母细胞瘤为29%,间变性星形细胞瘤/少突胶质细胞瘤为38%,其他脑肿瘤为31%。
- 儿童、成人、老年患者皮肤反应发生率分别为37%、34%、36%。
- 新诊断/复发胶质母细胞瘤患者中,阵列下热感(温暖感)发生率分别为11%和10%,电刺激感(刺痛感)分别为11%和9%,头痛分别为7%和6%。
- 大多数皮肤不良事件为轻中度且可控。
临床怎么用
- 临床实践中应关注TTFields治疗患者的皮肤反应,多数为轻中度且可控,无需因此中断治疗。
- 老年和儿童患者使用TTFields的安全性与其他人群一致,可考虑在多个人群中应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Tumor Treating Fields (TTFields; antimitotic treatment) delivers low-intensity, intermediate-frequency, alternating electric fields through skin-applied transducer arrays. TTFields (200 kHz) was FDA-approved in glioblastoma (GBM), based on the phase 3 EF-11 (recurrent GBM, rGBM) and EF-14 (newly diagnosed GBM, ndGBM) trials. The most common TTFields-related adverse event (AE) in both trials was array-associated skin irritation. We now report on TTFields-related AEs in the real-world, clinical practice setting. METHODS: Unsolicited, post-marketing surveillance data from TTFields-treated patients (October 2011-February 2019) were retrospectively analyzed using MedDRA v21.1 preferred terms, stratified by region (US, EMEA [Europe, Middle East, Africa], Japan), diagnosis (ndGBM, rGBM, anaplastic astrocytoma/oligodendroglioma, other brain tumors), and age (< 18 [pediatric], 18-64 [adults], ≥ 65 [elderly]; years of age). RESULTS: Of 11,029 patients, 53% were diagnosed with ndGBM and 39% were diagnosed with rGBM at any line of disease recurrence. Most were adults (73%), 26% were elderly, and the male-to-female ratio was ~ 2:1 (close to published ratios of typical GBM populations). The most commonly reported TTFields-related AE was array-associated skin reaction, occurring in patients with ndGBM (38%), rGBM (29%), anaplastic astrocytoma/oligodendroglioma (38%), and other brain tumors (31%); as well as 37% of pediatric, 34% of adult, and 36% of elderly patients. Most skin AEs were mild/moderate and manageable. Other TTFields-related AEs in patients with ndGBM/rGBM included under-array heat sensation (warmth; 11%, 10%, respectively) and electric sensation (tingling; 11%, 9%, respectively), and headache (7%, 6%, respectively). CONCLUSIONS: This TTFields safety surveillance analysis in > 11,000 patients revealed no new safety concerns, with a favorable safety profile comparable with published TTFields/GBM trials. The safety profile remained consistent among subgroups, suggesting feasibility in multiple populations, including elderly patients.
引用
- Shi W, Blumenthal DT, Oberheim Bush NA, et al. Global post-marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high-grade glioma in clinical practice. J Neurooncol. 2020. PMID: 32535723. doi:10.1007/s11060-020-03540-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。